MARKET OUTLOOK

North America’s building integrated photovoltaics market is estimated to garner a compound annual growth rate of 17.13% over the forecasting years from 2023 to 2030. Canada and the United States are examined in the given region.
The real estate sector has been growing in urban areas over the past decade in Canada. The Bank of Montreal reported a significant rise in condominium construction. Estimates suggest that the highest construction activity concentration is witnessed in Toronto, Montreal, Vancouver, Edmonton, and Calgary. This rise in construction projects creates an opportunity for manufacturers of PVs. In this regard, the concentration of PV is high in Ontario, owing to attractive FITs for solar power. Therefore, the rise in construction activities and government initiatives is opening new avenues for the building integrated photovoltaics market.
In the US, the looming carbon taxes, falling PV costs, and PV subsidy programs have supported the expansion of the studied market. The dominance of the roofing sector is mainly on account of large industrial infrastructure projects, including warehouses, terminals, and factories. Further, the construction of commercial buildings, such as shopping centers, airline terminals, etc., provides an excellent opportunity for efficient power generation for the BIPV market.

COMPETITIVE OUTLOOK
The key companies in the building integrated photovoltaics market include AGC Inc, SunPower Corporation, Heliatek, ClearVue Technologies Limited, and Kaneka Corporation.

TABLE OF CONTENTS

1. NORTH AMERICA BUILDING INTEGRATED PHOTOVOLTAICS MARKET – SUMMARY
2. INDUSTRY OUTLOOK
2.1. PARENT MARKET ANALYSIS
2.2. IMPACT ANALYSIS ON THE BUILDING INTEGRATED PHOTOVOLTAICS MARKET
2.2.1. COVID-19 IMPACT ON THE BUILDING INTEGRATED PHOTOVOLTAICS MARKET
2.3. PORTER’S FIVE FORCES ANALYSIS
2.3.1. THREAT OF NEW ENTRANTS
2.3.2. THREAT OF SUBSTITUTES
2.3.3. BARGAINING POWER OF BUYERS
2.3.4. BARGAINING POWER OF SUPPLIERS
2.3.5. THREAT OF COMPETITIVE RIVALRY
2.4. INDUSTRY COMPONENTS
2.4.1. COMPONENT MANUFACTURER
2.4.2. BUILDING INTEGRATED PHOTOVOLTAIC MANUFACTURERS
2.4.3. END-USERS
2.5. REGULATORY FRAMEWORK
2.6. KEY BUYING ANALYSIS
2.6.1. SUPERIOR TECHNOLOGY
2.6.2. APPLICATION
2.6.3. EFFICIENCY
2.6.4. RELIABILITY
2.7. KEY MARKET STRATEGIES
2.7.1. COLLABORATIONS
2.7.2. PRODUCT LAUNCHES
2.7.3. MERGERS & ACQUISITIONS
2.8. MARKET DRIVERS
2.8.1. REDUCTION OF CARBON FOOTPRINT
2.8.2. HIGH DEMAND FOR ENERGY
2.8.3. GROWING GOVERNMENT INITIATIVES TO STANDARDIZE INTEGRATED PHOTOVOLTAIC PRODUCTS FOR BUILDINGS
2.9. MARKET CHALLENGE
2.9.1. SLOW GROWTH OF SOLAR ENERGY IN THE NORTHERN REGIONS LIKE ALASKA
2.10. MARKET OPPORTUNITIES
2.10.1. RISE IN ROOFTOP SOLAR SYSTEMS FOR HOMES AND BUSINESSES
2.10.2. HIGH EFFICIENCY AND SIGNIFICANT COST REDUCTION IN THE SOLAR PV SEGMENT
2.10.3. RISING NEED FOR SUSTAINABLE AND CLEAN ENERGY
2.10.4. INCREASE IN RENEWABLE ENERGY INVESTMENT
2.11. ANALYST PERSPECTIVE
3. NORTH AMERICA BUILDING INTEGRATED PHOTOVOLTAICS MARKET – BY TECHNOLOGY
3.1. CRYSTALLINE SILICON
3.1.1. MONOCRYSTALLINE
3.1.2. POLYCRYSTALLINE
3.2. THIN FILM
3.3. OTHER TECHNOLOGIES
4. NORTH AMERICA BUILDING INTEGRATED PHOTOVOLTAICS MARKET – BY APPLICATION
4.1. ROOFING
4.2. GLAZING
4.3. FACADES
4.4. ARCHITECTURAL SHADING
5. NORTH AMERICA BUILDING INTEGRATED PHOTOVOLTAICS MARKET – BY INDUSTRY VERTICAL
5.1. INDUSTRIAL
5.2. COMMERCIAL
5.3. RESIDENTIAL
6. NORTH AMERICA BUILDING INTEGRATED PHOTOVOLTAICS MARKET – BY COUNTRY OUTLOOK
6.1. UNITED STATES
6.1.1. UNITED STATES BUILDING INTEGRATED PHOTOVOLTAICS MARKET FORECAST & PROSPECTS
6.2. CANADA
6.2.1. CANADA BUILDING INTEGRATED PHOTOVOLTAICS MARKET FORECAST & PROSPECTS
7. COMPETITIVE LANDSCAPE
7.1. AGC INC
7.1.1. OVERVIEW
7.1.2. FINANCIAL OVERVIEW
7.1.3. PRODUCT PORTFOLIO
7.1.4. KEY STRENGTHS
7.1.5. KEY CHALLENGES
7.2. HELIATEK
7.2.1. OVERVIEW
7.2.2. PRODUCT PORTFOLIO
7.2.3. KEY STRENGTHS
7.2.4. KEY CHALLENGES
7.3. CLEARVUE TECHNOLOGIES LIMITED
7.3.1. OVERVIEW
7.3.2. FINANCIAL OVERVIEW
7.3.3. PRODUCT PORTFOLIO
7.3.4. KEY STRENGTHS
7.3.5. KEY CHALLENGES
7.4. WAAREE ENERGIES LTD
7.4.1. OVERVIEW
7.4.2. FINANCIAL OVERVIEW
7.4.3. PRODUCT PORTFOLIO
7.4.4. KEY STRENGTHS
7.4.5. KEY CHALLENGES
7.5. KANEKA CORPORATION
7.5.1. OVERVIEW
7.5.2. FINANCIAL OVERVIEW
7.5.3. PRODUCT PORTFOLIO
7.5.4. KEY STRENGTHS
7.5.5. KEY CHALLENGES
7.6. TESLA INC
7.6.1. OVERVIEW
7.6.2. FINANCIAL OVERVIEW
7.6.3. PRODUCT PORTFOLIO
7.6.4. KEY STRENGTHS
7.6.5. KEY CHALLENGES
7.7. SUNPOWER CORPORATION
7.7.1. OVERVIEW
7.7.2. FINANCIAL OVERVIEW
7.7.3. PRODUCT PORTFOLIO
7.7.4. KEY STRENGTHS
7.7.5. KEY CHALLENGES
7.8. SAULE TECHNOLOGIES
7.8.1. OVERVIEW
7.8.2. PRODUCT PORTFOLIO
7.8.3. KEY STRENGTHS
7.8.4. KEY CHALLENGES
7.9. ERTEX SOLAR TECHNIK GMBH
7.9.1. OVERVIEW
7.9.2. PRODUCT PORTFOLIO
7.9.3. KEY STRENGTHS
7.9.4. KEY CHALLENGES
7.10. METSOLAR
7.10.1. OVERVIEW
7.10.2. PRODUCT PORTFOLIO
7.10.3. KEY STRENGTHS
7.10.4. KEY CHALLENGES
8. RESEARCH METHODOLOGY & SCOPE
8.1. RESEARCH SCOPE & DELIVERABLES
8.2. SOURCES OF DATA
8.3. RESEARCH METHODOLOGY

TABLE LIST

TABLE 1: NORTH AMERICA BUILDING INTEGRATED PHOTOVOLTAICS MARKET, BY COUNTRY OUTLOOK, 2023-2030 (IN $ MILLION)
TABLE 2: REGULATORY FRAMEWORK
TABLE 3: LIST OF COLLABORATION
TABLE 4: LIST OF PRODUCT LAUNCHES
TABLE 5: LIST OF MERGERS & ACQUISITIONS
TABLE 6: KG/BILLIONS OF CO2 EMITTED PER MILLION BTU OF ENERGY BY FUEL
TABLE 7: SHARE OF POPULATION WITH ACCESS TO ELECTRICITY IN 2020 (IN%)
TABLE 8: BUILDING-INTEGRATED PHOTOVOLTAIC (BIPV) PATENTS SHARE, BY COMPANY, 2021 (IN %)
TABLE 9: NORTH AMERICA BUILDING INTEGRATED PHOTOVOLTAICS MARKET, BY TECHNOLOGY, 2023-2030 (IN $ MILLION)
TABLE 10: NORTH AMERICA BUILDING INTEGRATED PHOTOVOLTAICS MARKET, BY CRYSTALLINE SILICON, 2023-2030 (IN $ MILLION)
TABLE 11: NORTH AMERICA BUILDING INTEGRATED PHOTOVOLTAICS MARKET, BY APPLICATION, 2023-2030 (IN $ MILLION)
TABLE 12: NORTH AMERICA BUILDING INTEGRATED PHOTOVOLTAICS MARKET, BY INDUSTRY VERTICAL, 2023-2030 (IN $ MILLION)
TABLE 13: NORTH AMERICA BUILDING INTEGRATED PHOTOVOLTAICS MARKET, BY COUNTRY OUTLOOK, 2023-2030 (IN $ MILLION)
TABLE 14: AGC INC – COMPANY OPERATING EXPENSES & EBITDA IN 2019-2021 (IN $ BILLION)

FIGURE LIST

FIGURE 1: PARENT MARKET FLOWCHART FOR BIPV
FIGURE 2: INDUSTRY COMPONENTS
FIGURE 3: KEY BUYING ANALYSIS
FIGURE 4: BIPV STAKEHOLDERS’ ECOSYSTEM
FIGURE 5: PATENTS PUBLISHED ON BIPV TECHNOLOGIES 2017-2022 (NUMBER)
FIGURE 6: BIPV PATENT SHARES, BY ASSIGNEE COUNTRY, 2021 (IN %)
FIGURE 7: NORTH AMERICA BUILDING INTEGRATED PHOTOVOLTAICS MARKET, BY TECHNOLOGY, 2022 & 2030 (IN %)
FIGURE 8: NORTH AMERICA BUILDING INTEGRATED PHOTOVOLTAICS MARKET, BY CRYSTALLINE SILICON, 2023-2030 (IN $ MILLION)
FIGURE 9: NORTH AMERICA BUILDING INTEGRATED PHOTOVOLTAICS MARKET, BY CRYSTALLINE SILICON, 2022 & 2030 (IN %)
FIGURE 10: NORTH AMERICA BUILDING INTEGRATED PHOTOVOLTAICS MARKET, BY MONOCRYSTALLINE, 2023-2030 (IN $ MILLION)
FIGURE 11: NORTH AMERICA BUILDING INTEGRATED PHOTOVOLTAICS MARKET, BY APPLICATION, 2022 & 2030 (IN %)
FIGURE 12: NORTH AMERICA BUILDING INTEGRATED PHOTOVOLTAICS MARKET, BY ROOFING, 2023-2030 (IN $ MILLION)
FIGURE 13: NORTH AMERICA BUILDING INTEGRATED PHOTOVOLTAICS MARKET, BY GLAZING, 2023-2030 (IN $ MILLION)
FIGURE 14: NORTH AMERICA BUILDING INTEGRATED PHOTOVOLTAICS MARKET, BY FACADES, 2023-2030 (IN $ MILLION)
FIGURE 15: NORTH AMERICA BUILDING INTEGRATED PHOTOVOLTAICS MARKET, BY ARCHITECTURAL SHADING, 2023-2030 (IN $ MILLION)
FIGURE 16: NORTH AMERICA BUILDING INTEGRATED PHOTOVOLTAICS MARKET, BY INDUSTRY VERTICAL, 2022 & 2030 (IN %)
FIGURE 17: NORTH AMERICA BUILDING INTEGRATED PHOTOVOLTAICS MARKET, BY INDUSTRIAL, 2023-2030 (IN $ MILLION)
FIGURE 18: NORTH AMERICA BUILDING INTEGRATED PHOTOVOLTAICS MARKET, BY COMMERCIAL, 2023-2030 (IN $ MILLION)
FIGURE 19: NORTH AMERICA BUILDING INTEGRATED PHOTOVOLTAICS MARKET, BY RESIDENTIAL, 2023-2030 (IN $ MILLION)
FIGURE 20: NORTH AMERICA BUILDING INTEGRATED PHOTOVOLTAICS MARKET, BY COUNTRY OUTLOOK, 2022 & 2030 (IN %)
FIGURE 21: UNITED STATES BUILDING INTEGRATED PHOTOVOLTAICS MARKET 2023-2030 (IN $ MILLION)
FIGURE 22: CANADA BUILDING INTEGRATED PHOTOVOLTAICS MARKET 2023-2030 (IN $ MILLION)
FIGURE 23: AGC INC – COMPANY REVENUE IN 2019-2021 (IN $ BILLION)
FIGURE 24: AGC INC – COMPANY NET INCOME IN 2019-2021 (IN $ BILLION)
FIGURE 25: AGC INC – COMPANY REVENUE, BY REGION, IN 2021 (IN %)
FIGURE 26: CLEARVUE TECHNOLOGIES LIMITED – COMPANY REVENUE IN 2019-2021 (IN $ MILLION)
FIGURE 27: WAAREE ENERGIES LTD- COMPANY REVENUE IN 2019-2021 (IN $ MILLION)
FIGURE 28: WAAREE ENERGIES LTD – COMPANY NET INCOME IN 2019-2021 (IN $ MILLION)
FIGURE 29: KANEKA CORPORATION – COMPANY REVENUE IN 2019-2021 (IN $ MILLION)
FIGURE 30: KANEKA CORPORATION – COMPANY SALES, BY BUSINESS SEGMENT, IN 2021 (IN %)
FIGURE 31: KANEKA CORPORATION – COMPANY REVENUE, BY REGION, IN 2021 (IN %)
FIGURE 32: TESLA INC – COMPANY REVENUE IN 2019-2021 (IN $ MILLION)
FIGURE 33: TESLA INC – COMPANY SALES, BY BUSINESS SEGMENT, IN 2021 (IN %)
FIGURE 34: TESLA INC – COMPANY REVENUE, BY REGION, IN 2021 (IN %)
FIGURE 35: SUNPOWER CORPORATION – COMPANY REVENUE IN 2019-2021 (IN $ MILLION)
FIGURE 36: SUNPOWER CORPORATION – COMPANY SALES, BY BUSINESS SEGMENT, IN 2021 (IN %)

The post NORTH AMERICA BUILDING INTEGRATED PHOTOVOLTAICS MARKET 2023-2030 first appeared on CRI Report.

MARKET OUTLOOK

This report indicates that the epilepsy devices market in Europe is anticipated to propel at a compound annual growth rate of 7.94% in revenue during the forecast years 2022-2028. Spain, France, Germany, Italy, the United Kingdom, and the Rest of Europe are evaluated in the region.
In the United Kingdom, patients diagnosed with epilepsy experienced more psychological anguish during the pandemic, leading to high-level seizures. Several young people with epilepsy experienced behavioral and mental health issues. As a result, the aggravation of pre-existing mental health and behavioral disorder is expected to increase the sales of epilepsy monitoring equipment, thereby driving the studied market.
On the other hand, the National Health Services of Italy offer free medical attention to the people. In this regard, people with chronic conditions are entitled to full exemption from paying for medical treatments, diagnostic procedures, etc. During the pandemic, chronic neurological illness lacked medical attention, resulting in high seizure frequency among patients. Therefore, such factors have increased the demand for epilepsy treatments, creating opportunities for the epilepsy devices market across Italy.

COMPETITIVE OUTLOOK

The leading companies in the epilepsy devices market include LivaNova Plc, Natus Medical Incorporated, Cadwell Industries Inc, Medtronic Plc, Koninklijke Philips NV, and Empatica Inc.

TABLE OF CONTENTS

1. EUROPE EPILEPSY DEVICES MARKET – SUMMARY
2. INDUSTRY OUTLOOK
2.1. IMPACT OF COVID-19 ON THE EPILEPSY DEVICES MARKET
2.2. KEY INSIGHTS
2.2.1. GROWING USE OF TELEMEDICINE SERVICES
2.2.2. INCREASE IN DRUG AND DEVICE TRIALS FOR EPILEPSY
2.3. PORTER’S FIVE FORCES ANALYSIS
2.3.1. THREAT OF NEW ENTRANTS
2.3.2. THREAT OF SUBSTITUTES
2.3.3. BARGAINING POWER OF BUYERS
2.3.4. BARGAINING POWER OF SUPPLIERS
2.3.5. THREAT OF COMPETITIVE RIVALRY
2.4. KEY BUYING IMPACT ANALYSIS
2.4.1. COMFORT & USABILITY
2.4.2. PRODUCT FEATURES
2.4.3. CONFIDENTIALITY
2.5. MARKET ATTRACTIVENESS INDEX
2.6. VENDOR SCORECARD
2.7. INDUSTRY COMPONENTS
2.8. REGULATORY FRAMEWORK
2.9. KEY MARKET STRATEGIES
2.9.1. DEVELOPMENTS & PRODUCT LAUNCHES
2.9.2. COLLABORATIONS
2.9.3. ACQUISITIONS
2.10. MARKET DRIVERS
2.10.1. COMBATING EPILEPSY THROUGH EARLY DETECTION AND DIAGNOSIS
2.10.2. RISING PREVALENCE OF EPILEPSY
2.11. MARKET CHALLENGES
2.11.1. UNAWARENESS ABOUT EPILEPSY AMONG THE GENERAL MASSES
2.11.2. LACK OF NEUROLOGY SPECIALISTS IN THE HEALTHCARE SYSTEM
2.12. MARKET OPPORTUNITIES
2.12.1. R&D ACTIVITIES DUE TO GROWING EPILEPSY CASES IN OLD PEOPLE
2.12.2. ASCENDING POST-TRAUMATIC EPILEPSY (PTE) CASES DUE TO BRAIN INJURIES
2.12.3. TECHNOLOGICAL ADVANCES IN NON-INVASIVE WEARABLE SENSORS
3. EUROPE EPILEPSY DEVICES MARKET OUTLOOK – BY DEVICE TYPE
3.1. TRADITIONAL DEVICES
3.2. WEARABLE DEVICES
3.2.1. WATCHES
3.2.2. BRACELETS
3.2.3. CAMERA DEVICES
3.2.4. MATTRESS DEVICES
3.2.5. ANTI-SUFFOCATION PILLOWS
3.2.6. OTHER WEARABLE DEVICES
3.3. IMPLANTABLE DEVICES
4. EUROPE EPILEPSY DEVICES MARKET OUTLOOK – BY APPLICATION
4.1. VAGUS NERVE STIMULATION
4.2. DEEP BRAIN STIMULATION
4.2.1. MOVEMENT DISORDERS
4.2.2. EPILEPSY
4.3. ACCELEROMETER
4.4. RESPONSIVE NEUROSTIMULATION
5. EUROPE EPILEPSY DEVICES MARKET OUTLOOK – BY DETECTION AND PREDICTION DEVICE TYPE
5.1. ELECTROENCEPHALOGRAM
5.2. INTRACRANIAL EEG
5.3. SURFACE ELECTROMYOGRAPHY
5.4. ELECTROCARDIOGRAPHY
5.5. VIDEO DETECTION SYSTEMS
5.6. ELECTRODERMAL ACTIVITY
5.7. IMPLANTED ADVISORY SYSTEMS
5.8. OTHER DETECTION AND PREDICTION DEVICE TYPES
6. EUROPE EPILEPSY DEVICES MARKET OUTLOOK – BY END-USER
6.1. HOSPITALS & CLINICS
6.2. NEUROLOGY CENTERS
6.3. HOMECARE SETTINGS
6.4. OTHER END-USERS
7. EUROPE EPILEPSY DEVICES MARKET – COUNTRY OUTLOOK
7.1. UNITED KINGDOM
7.2. GERMANY
7.3. FRANCE
7.4. ITALY
7.5. SPAIN
7.6. REST OF EUROPE
8. COMPETITIVE LANDSCAPE
8.1. LIVANOVA PLC
8.2. NATUS MEDICAL INCORPORATED
8.3. CADWELL INDUSTRIES INC
8.4. NIHON KOHDEN CORPORATION
8.5. COMPUMEDICS LIMITED
8.6. MEDTRONIC PLC
8.7. BOSTON SCIENTIFIC CORPORATION
8.8. EMPATICA INC
8.9. KONINKLIJKE PHILIPS NV
8.10. NEUROPACE INC
8.11. DRÄGERWERK AG & CO KGAA
8.12. SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO LTD
8.13. NEUROSOFT
9. RESEARCH METHODOLOGY & SCOPE
9.1. RESEARCH SCOPE & DELIVERABLES
9.2. SOURCES OF DATA
9.3. RESEARCH METHODOLOGY

LIST OF TABLES
TABLE 1: EUROPE EPILEPSY DEVICES MARKET, BY COUNTRY OUTLOOK, 2022-2028 (IN $ MILLION)
TABLE 2: VENDOR SCORECARD
TABLE 3: REGULATORY FRAMEWORK
TABLE 4: LIST OF PRODUCT LAUNCHES
TABLE 5: LIST OF COLLABORATIONS
TABLE 6: LIST OF ACQUISITIONS
TABLE 7: EXAMPLES OF ANTIEPILEPTIC DRUGS FOR THE ELDERLY AND THEIR ADVANTAGES
TABLE 8: EXAMPLE OF MOBILE EEG DEVICES
TABLE 9: EUROPE EPILEPSY DEVICES MARKET, BY DEVICE TYPE, 2022-2028 (IN $ MILLION)
TABLE 10: EUROPE EPILEPSY DEVICES MARKET, BY WEARABLE DEVICES, 2022-2028 (IN $ MILLION)
TABLE 11: EUROPE EPILEPSY DEVICES MARKET, BY APPLICATION, 2022-2028 (IN $ MILLION)
TABLE 12: EUROPE EPILEPSY DEVICES MARKET, BY DEEP BRAIN STIMULATION, 2022-2028 (IN $ MILLION)
TABLE 13: EUROPE EPILEPSY DEVICES MARKET, BY DETECTION AND PREDICTION DEVICE TYPE, 2022-2028 (IN $ MILLION)
TABLE 14: EUROPE EPILEPSY DEVICES MARKET, BY END-USER, 2022-2028 (IN $ MILLION)
TABLE 15: EUROPE EPILEPSY DEVICES MARKET, BY COUNTRY OUTLOOK, 2022-2028 (IN $ MILLION)

LIST OF FIGURES
FIGURE 1: KEY BUYING IMPACT ANALYSIS
FIGURE 2: MARKET ATTRACTIVENESS INDEX
FIGURE 3: INDUSTRY COMPONENTS
FIGURE 4: EUROPE EPILEPSY DEVICES MARKET, BY DEVICE TYPE, 2021 & 2028 (IN %)
FIGURE 5: EUROPE EPILEPSY DEVICES MARKET, BY TRADITIONAL DEVICES, 2022-2028 (IN $ MILLION)
FIGURE 6: EUROPE EPILEPSY DEVICES MARKET, BY WEARABLE DEVICES, 2022-2028 (IN $ MILLION)
FIGURE 7: EUROPE EPILEPSY DEVICES MARKET, BY WEARABLE DEVICES, 2021 & 2028 (IN %)
FIGURE 8: EUROPE EPILEPSY DEVICES MARKET, BY WATCHES, 2022-2028 (IN $ MILLION)
FIGURE 9: EUROPE EPILEPSY DEVICES MARKET, BY BRACELETS, 2022-2028 (IN $ MILLION)
FIGURE 10: EUROPE EPILEPSY DEVICES MARKET, BY CAMERA DEVICES, 2022-2028 (IN $ MILLION)
FIGURE 11: EUROPE EPILEPSY DEVICES MARKET, BY MATTRESS DEVICES, 2022-2028 (IN $ MILLION)
FIGURE 12: EUROPE EPILEPSY DEVICES MARKET, BY ANTI-SUFFOCATION PILLOWS, 2022-2028 (IN $ MILLION)
FIGURE 13: EUROPE EPILEPSY DEVICES MARKET, BY OTHER WEARABLE DEVICES, 2022-2028 (IN $ MILLION)
FIGURE 14: EUROPE EPILEPSY DEVICES MARKET, BY IMPLANTABLE DEVICES, 2022-2028 (IN $ MILLION)
FIGURE 15: EUROPE EPILEPSY DEVICES MARKET, BY APPLICATION, 2021 & 2028 (IN %)
FIGURE 16: EUROPE EPILEPSY DEVICES MARKET, BY VAGUS NERVE STIMULATION, 2022-2028 (IN $ MILLION)
FIGURE 17: EUROPE EPILEPSY DEVICES MARKET, BY DEEP BRAIN STIMULATION, 2022-2028 (IN $ MILLION)
FIGURE 18: EUROPE EPILEPSY DEVICES MARKET, BY DEEP BRAIN STIMULATION, 2021 & 2028 (IN %)
FIGURE 19: EUROPE EPILEPSY DEVICES MARKET, BY MOVEMENT DISORDERS, 2022-2028 (IN $ MILLION)
FIGURE 20: EUROPE EPILEPSY DEVICES MARKET, BY EPILEPSY, 2022-2028 (IN $ MILLION)
FIGURE 21: EUROPE EPILEPSY DEVICES MARKET, BY ACCELEROMETER, 2022-2028 (IN $ MILLION)
FIGURE 22: EUROPE EPILEPSY DEVICES MARKET, BY RESPONSIVE NEUROSTIMULATION, 2022-2028 (IN $ MILLION)
FIGURE 23: EUROPE EPILEPSY DEVICES MARKET, BY DETECTION AND PREDICTION DEVICE TYPE, 2021 & 2028 (IN %)
FIGURE 24: EUROPE EPILEPSY DEVICES MARKET, BY ELECTROENCEPHALOGRAM, 2022-2028 (IN $ MILLION)
FIGURE 25: EUROPE EPILEPSY DEVICES MARKET, BY INTRACRANIAL EEG, 2022-2028 (IN $ MILLION)
FIGURE 26: EUROPE EPILEPSY DEVICES MARKET, BY SURFACE ELECTROMYOGRAPHY, 2022-2028 (IN $ MILLION)
FIGURE 27: EUROPE EPILEPSY DEVICES MARKET, BY ELECTROCARDIOGRAPHY, 2022-2028 (IN $ MILLION)
FIGURE 28: EUROPE EPILEPSY DEVICES MARKET, BY VIDEO DETECTION SYSTEMS, 2022-2028 (IN $ MILLION)
FIGURE 29: EUROPE EPILEPSY DEVICES MARKET, BY ELECTRODERMAL ACTIVITY, 2022-2028 (IN $ MILLION)
FIGURE 30: EUROPE EPILEPSY DEVICES MARKET, BY IMPLANTED ADVISORY SYSTEMS, 2022-2028 (IN $ MILLION)
FIGURE 31: EUROPE EPILEPSY DEVICES MARKET, BY OTHER PREDICTION AND DETECTION DEVICE TYPES, 2022-2028 (IN $ MILLION)
FIGURE 32: EUROPE EPILEPSY DEVICES MARKET, BY END-USER, 2021 & 2028 (IN %)
FIGURE 33: EUROPE EPILEPSY DEVICES MARKET, BY HOSPITALS & CLINICS, 2022-2028 (IN $ MILLION)
FIGURE 34: EUROPE EPILEPSY DEVICES MARKET, BY NEUROLOGY CENTERS, 2022-2028 (IN $ MILLION)
FIGURE 35: EUROPE EPILEPSY DEVICES MARKET, BY HOMECARE SETTINGS, 2022-2028 (IN $ MILLION)
FIGURE 36: EUROPE EPILEPSY DEVICES MARKET, BY OTHER END-USERS, 2022-2028 (IN $ MILLION)
FIGURE 37: EUROPE EPILEPSY DEVICES MARKET, BY COUNTRY OUTLOOK, 2021 & 2028 (IN %)
FIGURE 38: UNITED KINGDOM EPILEPSY DEVICES MARKET 2022-2028 (IN $ MILLION)
FIGURE 39: GERMANY EPILEPSY DEVICES MARKET 2022-2028 (IN $ MILLION)
FIGURE 40: FRANCE EPILEPSY DEVICES MARKET 2022-2028 (IN $ MILLION)
FIGURE 41: ITALY EPILEPSY DEVICES MARKET 2022-2028 (IN $ MILLION)
FIGURE 42: SPAIN EPILEPSY DEVICES MARKET 2022-2028 (IN $ MILLION)
FIGURE 43: REST OF EUROPE EPILEPSY DEVICES MARKET 2022-2028 (IN $ MILLION)

The post EUROPE EPILEPSY DEVICES MARKET 2022-2028 first appeared on CRI Report.

The study by CRI highlights that the North America market is predicted to surge at a CAGR of 6.03% during the forecast period 2022-2028. The countries considered in the market in the region include United States and Canada.
In the United States, rapidly integrating electronic information and command systems into military vehicles has become necessary over the past several years. These systems are now networked, sharing information with ground combatants and across and within the same platform. In August 2021, US Army land warfare experts selected five military firms to manufacture the Army M2 Bradley Fighting Vehicle replacement’s next-generation fast armored combat vehicles and vetronics architect. Additionally, the US Army announced five contracts amounting to $26.6 million each for the phase-two concept design of the optionally manned fighting vehicle (OMFV). Such developments can boost the country’s market growth.
In Canada, the M113 and LAV-II (Bison) fleets are being replaced by the Armored Combat Support Vehicle (LAV 6.0). Large and light armored fighting vehicles will be supported by it on the battlefield. The Canadian Army is aiming for another fleet of non-lethal unmanned ground vehicles (NUGVs) for search and rescue, CBRN, and casualty extraction under its Future Family of UGVs initiative. Additionally, 66 LAV 6.0 chassis will replace the Coyote Reconnaissance Vehicle under a project known as the light armored vehicle reconnaissance surveillance system. Thus, such additions to the Canadian Army can surge the studied market’s growth.

COMPETITIVE OUTLOOK

The established players in the vetronics market include Curtiss-Wright, Lockheed Martin Corporation, Thales Group, Raytheon Technologies and Saab AB.

TABLE OF CONTENTS

1. NORTH AMERICA VETRONICS MARKET – SUMMARY
2. INDUSTRY OUTLOOK
2.1. IMPACT OF COVID-19 ON THE VETRONICS MARKET
2.2. KEY INSIGHTS
2.2.1. GROWING INVESTMENTS IN HYBRID MILITARY VEHICLES
2.2.2. RISING MILITARY LAND-VEHICLE INVENTORY
2.3. PORTER’S FIVE FORCES ANALYSIS
2.3.1. THREAT OF NEW ENTRANTS
2.3.2. THREAT OF SUBSTITUTES
2.3.3. BARGAINING POWER OF BUYERS
2.3.4. BARGAINING POWER OF SUPPLIERS
2.3.5. THREAT OF COMPETITIVE RIVALRY
2.4. MARKET ATTRACTIVENESS INDEX
2.5. VENDOR SCORECARD
2.6. INDUSTRY COMPONENTS
2.6.1. COMPONENT PROVIDERS
2.6.2. SYSTEM MANUFACTURERS/OEMs
2.6.3. DISTRIBUTION CHANNELS
2.6.4. END-USERS
2.6.5. AFTERMARKET SERVICES
2.7. KEY MARKET STRATEGY
2.7.1. ACQUISITIONS
2.8. MARKET DRIVERS
2.8.1. OPEN ARCHITECTURE OF VETRONICS SYSTEMS
2.8.2. ONGOING MILITARY MODERNIZATION OF LAND-BASED VEHICLE INVENTORY
2.8.3. ADVANCEMENTS IN BATTLEFIELD TECHNOLOGY
2.9. MARKET CHALLENGES
2.9.1. CUT-OFFS IN DEFENSE BUDGET
2.9.2. RISING COST OF RAW MATERIALS
2.9.3. USABILITY REGULATIONS
2.10. MARKET OPPORTUNITIES
2.10.1. INVESTMENTS IN RESEARCH & DEVELOPMENT
2.10.2. GROWING VETRONICS MARKET IN THE UNITED STATES
3. NORTH AMERICA VETRONICS MARKET OUTLOOK – LAND-BASED FLEET TYPE
3.1. TANKS
3.2. ARMORED VEHICLES
3.3. ARTILLERY
3.4. ROCKET PROJECTORS
4. NORTH AMERICA VETRONICS MARKET OUTLOOK – BY COMPONENT
4.1. ELECTRONIC WARFARE & C4 SYSTEMS
4.2. NAVIGATION SYSTEMS
4.3. POWER SYSTEMS
4.4. VEHICLE PROTECTION SYSTEMS
5. NORTH AMERICA VETRONICS MARKET OUTLOOK – BY VERTICAL
5.1. DEFENSE
5.2. HOMELAND SECURITY
6. NORTH AMERICA VETRONICS MARKET – COUNTRY OUTLOOK
6.1. UNITED STATES
6.2. CANADA
7. COMPETITIVE LANDSCAPE
7.1. CURTISS-WRIGHT
7.2. BAE SYSTEMS
7.3. THALES GROUP
7.4. GENERAL DYNAMICS CORPORATION
7.5. LOCKHEED MARTIN CORPORATION
7.6. RHEINMETALL AG
7.7. RAYTHEON TECHNOLOGIES
7.8. L3HARRIS TECHNOLOGIES
7.9. SAAB AB
7.10. LEONARDO S.P.A
8. RESEARCH METHODOLOGY & SCOPE
8.1. RESEARCH SCOPE & DELIVERABLES
8.2. SOURCES OF DATA
8.3. RESEARCH METHODOLOGY

LIST OF TABLES

TABLE 1: NORTH AMERICA VETRONICS MARKET, COUNTRY OUTLOOK, 2022-2028 (IN $ MILLION)
TABLE 2: VENDOR SCORECARD
TABLE 3: LIST OF ACQUISITIONS
TABLE 4: NORTH AMERICA VETRONICS MARKET, BY LAND-BASED FLEET TYPE, 2022-2028 (IN $ MILLION)
TABLE 5: NORTH AMERICA VETRONICS MARKET, BY COMPONENT, 2022-2028 (IN $ MILLION)
TABLE 6: NORTH AMERICA VETRONICS MARKET, BY VERTICAL, 2022-2028 (IN $ MILLION)
TABLE 7: NORTH AMERICA VETRONICS MARKET, COUNTRY OUTLOOK, 2022-2028 (IN $ MILLION)

LIST OF FIGURES

FIGURE 1: MARKET ATTRACTIVENESS INDEX
FIGURE 2: NORTH AMERICA VETRONICS MARKET, BY LAND-BASED FLEET TYPE, 2021 & 2028 (IN %)
FIGURE 3: NORTH AMERICA VETRONICS MARKET, BY TANKS, 2022-2028 (IN $ MILLION)
FIGURE 4: NORTH AMERICA VETRONICS MARKET, BY ARMORED VEHICLES, 2022-2028 (IN $ MILLION)
FIGURE 5: NORTH AMERICA VETRONICS MARKET, BY ARTILLERY, 2022-2028 (IN $ MILLION)
FIGURE 6: NORTH AMERICA VETRONICS MARKET, BY ROCKET PROJECTORS, 2022-2028 (IN $ MILLION)
FIGURE 7: NORTH AMERICA VETRONICS MARKET, BY COMPONENT, 2021 & 2028 (IN %)
FIGURE 8: NORTH AMERICA VETRONICS MARKET, BY ELECTRONIC WARFARE & C4 SYSTEMS, 2022-2028 (IN $ MILLION)
FIGURE 9: NORTH AMERICA VETRONICS MARKET, BY NAVIGATION SYSTEMS, 2022-2028 (IN $ MILLION)
FIGURE 10: NORTH AMERICA VETRONICS MARKET, BY POWER SYSTEMS, 2022-2028 (IN $ MILLION)
FIGURE 11: NORTH AMERICA VETRONICS MARKET, BY VEHICLE PROTECTION SYSTEMS, 2022-2028 (IN $ MILLION)
FIGURE 12: NORTH AMERICA VETRONICS MARKET, BY VERTICAL, 2021 & 2028 (IN %)
FIGURE 13: NORTH AMERICA VETRONICS MARKET, BY DEFENSE, 2022-2028 (IN $ MILLION)
FIGURE 14: NORTH AMERICA VETRONICS MARKET, BY HOMELAND SECURITY, 2022-2028 (IN $ MILLION)
FIGURE 15: NORTH AMERICA VETRONICS MARKET, COUNTRY OUTLOOK, 2021 & 2028 (IN %)
FIGURE 16: UNITED STATES VETRONICS MARKET 2022-2028 (IN $ MILLION)
FIGURE 17: CANADA VETRONICS MARKET 2022-2028 (IN $ MILLION)

The post NORTH AMERICA VETRONICS MARKET 2022-2028 first appeared on CRI Report.

According to this report, the market for clinical trials support services in North America is anticipated to develop with a CAGR of 7.39% in the forecasted period 2022-2028. The United States and Canada are assessed in the market in this region.
There are several companies based in the US that operate in this field and offer various solutions. For instance, IQVIA offers a clinical trial management system, Syneos Health offers a decentralized solutions team & clinical project management solutions, Charles River Laboratories offers zygosity testing, Parexel offers biostatistics services, and many other companies offer similar services. The presence of several leading companies is aiding the growth of the United States’ market.
In Canada, hundreds of new clinical trials pertaining to medical drugs, vaccines, and others, take place. The nation accounts for 4% of the total global clinical trials conducted, and ranks fourth with respect to the number of clinical trials sites. Besides, it is also the leader among G7 countries in terms of clinical trials productivity. These factors influence the demand for support services to conduct these trials. This, in turn, is expected to foster the growth of the Canadian clinical trials support services market. Besides, the market is benefited by the availability of a large participant pool, as children and youth can also partake in the trial process after obtaining permission from their parents or caretakers.

COMPETITIVE OUTLOOK

Charles River Laboratories, PSI CRO, Advanced Clinical, Worldwide Clinical Trials, WuXi AppTec, CTI Clinical Trial and Consulting Services Inc, KCR, and Syneos Health are some of the eminent players in the clinical trials support services market.

TABLE OF CONTENTS

1. NORTH AMERICA CLINICAL TRIALS SUPPORT SERVICES MARKET – SUMMARY
2. INDUSTRY OUTLOOK
2.1. IMPACT OF COVID-19 ON THE CLINICAL TRIALS SUPPORT SERVICES MARKET
2.2. KEY INSIGHTS
2.2.1. KEY PLAYERS’ PROMISING COLLABORATIONS
2.2.2. INCREASE IN SCREENING TESTS
2.3. PORTER’S FIVE FORCES ANALYSIS
2.3.1. THREAT OF NEW ENTRANTS
2.3.2. THREAT OF SUBSTITUTES
2.3.3. BARGAINING POWER OF BUYERS
2.3.4. BARGAINING POWER OF SUPPLIERS
2.3.5. THREAT OF COMPETITIVE RIVALRY
2.4. KEY BUYING IMPACT ANALYSIS
2.4.1. PERFORMANCE
2.4.2. EASE OF USE
2.4.3. SECURITY
2.4.4. COST EFFECTIVENESS
2.5. MARKET ATTRACTIVENESS INDEX
2.6. VENDOR SCORECARD
2.7. INDUSTRY COMPONENTS
2.8. REGULATORY FRAMEWORK
2.9. KEY MARKET STRATEGIES
2.9.1. ACQUISITIONS
2.9.2. PRODUCT LAUNCHES
2.9.3. CONTRACTS & AGREEMENTS
2.9.4. INVESTMENTS & EXPANSIONS
2.10. MARKET DRIVERS
2.10.1. NEED TO OVERCOME THE BARRIERS IN CLINICAL TRIALS
2.10.2. RISE IN TRIALS DUE TO INCREASED DISEASE INCIDENCE
2.11. MARKET CHALLENGES
2.11.1. DELAYED APPROVAL DUE TO STRINGENT REGULATORY FRAMEWORK
2.11.2. USE OF OPEN-SOURCE SOFTWARE
2.12. MARKET OPPORTUNITIES
2.12.1. INCREASING DEMAND FOR VACCINES AND PHARMACEUTICALS
2.12.2. DATA MANAGEMENT SERVICE EXPECTED TO WITNESS NOTABLE GROWTH
2.12.3. ACQUISITIONS IN THE CLINICAL TRIALS SUPPORT SERVICES MARKET
3. NORTH AMERICA CLINICAL TRIALS SUPPORT SERVICES MARKET OUTLOOK – BY PHASE TYPE
3.1. PHASE I
3.2. PHASE II
3.3. PHASE III
3.4. PHASE IV
4. NORTH AMERICA CLINICAL TRIALS SUPPORT SERVICES MARKET OUTLOOK – BY SERVICE
4.1. CLINICAL TRIAL SITE MANAGEMENT
4.2. ADMINISTRATIVE SERVICES
4.3. PATIENT RECRUITMENT MANAGEMENT
4.4. REGULATORY SERVICES
4.5. DATA MANAGEMENT
4.6. OTHER SERVICES
5. NORTH AMERICA CLINICAL TRIALS SUPPORT SERVICES MARKET OUTLOOK – BY SPONSOR
5.1. PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES
5.2. MEDICAL DEVICE COMPANIES
5.3. OTHER SPONSORS
6. NORTH AMERICA CLINICAL TRIALS SUPPORT SERVICES MARKET – COUNTRY OUTLOOK
6.1. UNITED STATES
6.2. CANADA
7. COMPETITIVE LANDSCAPE
7.1. IQVIA
7.2. PAREXEL
7.3. ICON PLC
7.4. SYNEOS HEALTH
7.5. LABCORP DRUG DEVELOPMENT
7.6. CLINIPACE
7.7. KCR
7.8. CHARLES RIVER LABORATORIES
7.9. MEDPACE
7.10. ALCURA
7.11. PSI CRO
7.12. WORLDWIDE CLINICAL TRIALS
7.13. CTI CLINICAL TRIAL AND CONSULTING SERVICES INC
7.14. WUXI APPTEC
7.15. ADVANCED CLINICAL
8. RESEARCH METHODOLOGY & SCOPE
8.1. RESEARCH SCOPE & DELIVERABLES
8.2. SOURCES OF DATA
8.3. RESEARCH METHODOLOGY

TABLE LIST

TABLE 1: NORTH AMERICA CLINICAL TRIALS SUPPORT SERVICES MARKET, COUNTRY OUTLOOK, 2022-2028 (IN $ MILLION)
TABLE 2: LIST OF COLLABORATIONS
TABLE 3: VENDOR SCORECARD
TABLE 4: REGULATORY FRAMEWORK
TABLE 5: LIST OF ACQUISITIONS
TABLE 6: LIST OF PRODUCT LAUNCHES
TABLE 7: LIST OF CONTRACTS & AGREEMENTS
TABLE 8: LIST OF INVESTMENTS & BUSINESS EXPANSIONS
TABLE 9: LIST OF PANDEMIC OUTBREAKS
TABLE 10: LIST OF OPEN-SOURCE SOFTWARE
TABLE 11: LAUNCH OF MEDICAL DRUGS
TABLE 12: PROMISING ACQUISITIONS IN THE MARKET
TABLE 13: NORTH AMERICA CLINICAL TRIALS SUPPORT SERVICES MARKET, BY SERVICE, 2022-2028 (IN $ MILLION)
TABLE 14: NORTH AMERICA CLINICAL TRIALS SUPPORT SERVICES MARKET, BY PHASE TYPE, 2022-2028 (IN $ MILLION)
TABLE 15: NORTH AMERICA CLINICAL TRIALS SUPPORT SERVICES MARKET, BY SPONSOR, 2022-2028 (IN $ MILLION)
TABLE 16: NORTH AMERICA CLINICAL TRIALS SUPPORT SERVICES MARKET, COUNTRY OUTLOOK, 2022-2028 (IN $ MILLION)
TABLE 17: NUMBER AND TYPES OF REGISTERED STUDIES

FIGURE LIST

FIGURE 1: KEY BUYING IMPACT ANALYSIS
FIGURE 2: MARKET ATTRACTIVENESS INDEX
FIGURE 3: INDUSTRY COMPONENTS
FIGURE 4: NORTH AMERICA CLINICAL TRIALS SUPPORT SERVICES MARKET, BY PHASE TYPE, 2021 & 2028 (IN %)
FIGURE 5: NORTH AMERICA CLINICAL TRIALS SUPPORT SERVICES MARKET, BY PHASE I, 2022-2028 (IN $ MILLION)
FIGURE 6: NORTH AMERICA CLINICAL TRIALS SUPPORT SERVICES MARKET, BY PHASE II, 2022-2028 (IN $ MILLION)
FIGURE 7: NORTH AMERICA CLINICAL TRIALS SUPPORT SERVICES MARKET, BY PHASE III, 2022-2028 (IN $ MILLION)
FIGURE 8: NORTH AMERICA CLINICAL TRIALS SUPPORT SERVICES MARKET, BY PHASE IV, 2022-2028 (IN $ MILLION)
FIGURE 9: NORTH AMERICA CLINICAL TRIALS SUPPORT SERVICES MARKET, BY SERVICE, 2021 & 2028 (IN %)
FIGURE 10: NORTH AMERICA CLINICAL TRIALS SUPPORT SERVICES MARKET, BY CLINICAL TRIAL SITE MANAGEMENT, 2022-2028 (IN $ MILLION)
FIGURE 11: NORTH AMERICA CLINICAL TRIALS SUPPORT SERVICES MARKET, BY ADMINISTRATIVE SERVICES, 2022-2028 (IN $ MILLION)
FIGURE 12: NORTH AMERICA CLINICAL TRIALS SUPPORT SERVICES MARKET, BY PATIENT RECRUITMENT MANAGEMENT, 2022-2028 (IN $ MILLION)
FIGURE 13: NORTH AMERICA CLINICAL TRIALS SUPPORT SERVICES MARKET, BY REGULATORY SERVICES, 2022-2028 (IN $ MILLION)
FIGURE 14: NORTH AMERICA CLINICAL TRIALS SUPPORT SERVICES MARKET, BY DATA MANAGEMENT, 2022-2028 (IN $ MILLION)
FIGURE 15: NORTH AMERICA CLINICAL TRIALS SUPPORT SERVICES MARKET, BY OTHER SERVICES, 2022-2028 (IN $ MILLION)
FIGURE 16: NORTH AMERICA CLINICAL TRIALS SUPPORT SERVICES MARKET, BY SPONSOR, 2021 & 2028 (IN %)
FIGURE 17: NORTH AMERICA CLINICAL TRIALS SUPPORT SERVICES MARKET, BY PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, 2022-2028 (IN $ MILLION)
FIGURE 18: NORTH AMERICA CLINICAL TRIALS SUPPORT SERVICES MARKET, BY MEDICAL DEVICE COMPANIES, 2022-2028 (IN $ MILLION)
FIGURE 19: NORTH AMERICA CLINICAL TRIALS SUPPORT SERVICES MARKET, BY OTHER SPONSORS, 2022-2028 (IN $ MILLION)
FIGURE 20: NORTH AMERICA CLINICAL TRIALS SUPPORT SERVICES MARKET, COUNTRY OUTLOOK, 2021 & 2028 (IN %)
FIGURE 21: UNITED STATES CLINICAL TRIALS SUPPORT SERVICES MARKET, 2022-2028 (IN $ MILLION)
FIGURE 22: CANADA CLINICAL TRIALS SUPPORT SERVICES MARKET, 2022-2028 (IN $ MILLION)

The post NORTH AMERICA CLINICAL TRIALS SUPPORT SERVICES MARKET 2022-2028 first appeared on CRI Report.

According to this report, the companion diagnostics market in North America is evaluated to attain a compound annual growth rate of 12.96% over the forecasting years 2022 to 2028. The United States and Canada shape the market in the region.
In Canada, several public and private initiatives are expected to widen the scope of the studied market, despite limited healthcare policy. For instance, the Alliance for Innovation in Molecular Diagnostics is working to improve the companion diagnostics innovation environment. The initiatives also aim to decrease the lack of clarity on how decision-makers prioritize the CDx tests by highlighting the interprovincial regulations that deter CDx development and adoption.
Furthermore, HTA agencies, government agencies, and hospitals strive to promote CDx applications by providing reimbursements. Above all, innovative clinical trials, increased R&D investments, and healthcare plans are anticipated to fuel the Canadian companion diagnostics market’s growth over the forecast period.
In the US, the rapid evolution of diagnostics technologies and investments are increasing the demand for advanced diagnostic testing. Moreover, the recent developments favoring comprehensive CDx tests to gain the necessary information to make therapeutic decisions are responsible for propelling the companion diagnostics market on a growth path.

COMPETITIVE OUTLOOK

The notable companies thriving in the companion diagnostics market include Almac Group, GE Healthcare, Roche Diagnostics, Sysmex Corporation, and Abbott Laboratories.

TABLE OF CONTENTS

1. NORTH AMERICA COMPANION DIAGNOSTICS MARKET – SUMMARY
2. INDUSTRY OUTLOOK
2.1. IMPACT OF COVID-19 ON THE COMPANION DIAGNOSTICS MARKET
2.2. KEY INSIGHTS
2.2.1. COMMERCIAL SUCCESS OF PRECISION MEDICINE TREATMENT
2.2.2. ADOPTION OF PREDICTIVE BIOMARKERS
2.2.3. FUSION OF COMPUTER SCIENCE AND BIOLOGY
2.3. PORTER’S FIVE FORCES ANALYSIS
2.3.1. THREAT OF NEW ENTRANTS
2.3.2. THREAT OF SUBSTITUTES
2.3.3. BARGAINING POWER OF BUYERS
2.3.4. BARGAINING POWER OF SUPPLIERS
2.3.5. THREAT OF COMPETITIVE RIVALRY
2.4. KEY BUYING IMPACT ANALYSIS
2.4.1. COST
2.4.2. AVAILABILITY
2.4.3. SENSITIVITY & SPECIFICITY
2.4.4. EFFICACY
2.5. MARKET ATTRACTIVENESS INDEX
2.6. VENDOR SCORECARD
2.7. INDUSTRY COMPONENTS
2.8. REGULATORY FRAMEWORK
2.9. KEY MARKET STRATEGIES
2.9.1. ACQUISITIONS
2.9.2. PRODUCT LAUNCHES
2.9.3. CONTRACTS & AGREEMENTS
2.10. MARKET DRIVERS
2.10.1. INCREASE IN INCIDENCE OF MEDICATION REACTIONS
2.10.2. INCREASING PREVALENCE OF CANCER CASES AND FATALITIES
2.10.3. RISING PREVALENCE OF PRECISION MEDICINES
2.11. MARKET CHALLENGES
2.11.1. WEAK REIMBURSEMENT FRAMEWORK
2.11.2. COMMON CASES OF LEAKAGE IN ONCOLOGY COMPANION DIAGNOSTICS
2.12. MARKET OPPORTUNITY
2.12.1. ONGOING RESEARCH AND INVESTMENTS IN NEXT GENERATION GENE-SEQUENCING
3. NORTH AMERICA COMPANION DIAGNOSTICS MARKET OUTLOOK – BY MECHANISM
3.1. IN-SITU HYBRIDIZATION
3.2. POLYMERASE CHAIN REACTION
3.3. IMMUNOHISTOCHEMISTRY
3.4. NEXT GENERATION SEQUENCING
3.5. OTHER MECHANISMS
4. NORTH AMERICA COMPANION DIAGNOSTICS MARKET OUTLOOK – BY INDICATOR
4.1. ONCOLOGY
4.2. NEUROLOGY
4.3. INFECTIOUS DISEASES
4.4. OTHER INDICATORS
5. NORTH AMERICA COMPANION DIAGNOSTICS MARKET OUTLOOK – BY CONSUMER
5.1. PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES
5.2. REFERENCE LABORATORIES
5.3. OTHER CONSUMERS
6. NORTH AMERICA COMPANION DIAGNOSTICS MARKET OUTLOOK – BY COMMODITY
6.1. ASSAY KITS AND REAGENTS
6.2. SOFTWARE AND SERVICES
7. NORTH AMERICA COMPANION DIAGNOSTICS MARKET – COUNTRY OUTLOOK
7.1. UNITED STATES
7.2. CANADA
8. COMPETITIVE LANDSCAPE
8.1. ABBOTT LABORATORIES
8.2. ALMAC GROUP
8.3. ARUP LABORATORIES
8.4. BIOCARTIS
8.5. BIOMERIEUX
8.6. DANAHER CORPORATION
8.7. GE HEALTHCARE
8.8. GENOMIC HEALTH
8.9. ILLUMINA INC
8.10. MYRIAD GENETICS
8.11. QIAGEN
8.12. ROCHE DIAGNOSTICS
8.13. SYSMEX CORPORATION
8.14. THERMO FISHER SCIENTIFIC
8.15. AGILENT
9. RESEARCH METHODOLOGY & SCOPE
9.1. RESEARCH SCOPE & DELIVERABLES
9.2. SOURCES OF DATA
9.3. RESEARCH METHODOLOGY

LIST OF TABLES

TABLE 1: NORTH AMERICA COMPANION DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2022-2028 (IN $ MILLION)
TABLE 2: VENDOR SCORECARD
TABLE 3: LIST OF ACQUISITIONS
TABLE 4: LIST OF PRODUCT LAUNCHES
TABLE 5: LIST OF CONTRACTS & AGREEMENTS
TABLE 6: NUMBER OF CANCER PATIENTS IN 2020
TABLE 7: NORTH AMERICA COMPANION DIAGNOSTICS MARKET, OUTLOOK BY MECHANISM, 2022-2028 (IN $ MILLION)
TABLE 8: NORTH AMERICA COMPANION DIAGNOSTICS MARKET, OUTLOOK BY INDICATOR, 2022-2028 (IN $ MILLION)
TABLE 9: NORTH AMERICA COMPANION DIAGNOSTICS MARKET, OUTLOOK BY CONSUMER, 2022-2028 (IN $ MILLION)
TABLE 10: NORTH AMERICA COMPANION DIAGNOSTICS MARKET, OUTLOOK BY COMMODITY, 2022-2028 (IN $ MILLION)
TABLE 11: NORTH AMERICA COMPANION DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2022-2028 (IN $ MILLION)

LIST OF FIGURES

FIGURE 1: MARKET ATTRACTIVENESS INDEX
FIGURE 2: INDUSTRY COMPONENTS
FIGURE 3: FDA FRAMEWORK
FIGURE 4: CDX LEAKAGE POINTS
FIGURE 5: NORTH AMERICA COMPANION DIAGNOSTICS MARKET, OUTLOOK BY MECHANISM, 2021 & 2028 (IN %)
FIGURE 6: NORTH AMERICA COMPANION DIAGNOSTICS MARKET, BY IN-SITU HYBRIDIZATION, 2022-2028 (IN $ MILLION)
FIGURE 7: NORTH AMERICA COMPANION DIAGNOSTICS MARKET, BY POLYMERASE CHAIN REACTION, 2022-2028 (IN $ MILLION)
FIGURE 8: NORTH AMERICA COMPANION DIAGNOSTICS MARKET, BY IMMUNOHISTOCHEMISTRY, 2022-2028 (IN $ MILLION)
FIGURE 9: NORTH AMERICA COMPANION DIAGNOSTICS MARKET, BY NEXT GENERATION SEQUENCING, 2022-2028 (IN $ MILLION)
FIGURE 10: NORTH AMERICA COMPANION DIAGNOSTICS MARKET, BY OTHER MECHANISMS, 2022-2028 (IN $ MILLION)
FIGURE 11: NORTH AMERICA COMPANION DIAGNOSTICS MARKET, OUTLOOK BY INDICATOR, 2021 & 2028 (IN %)
FIGURE 12: NORTH AMERICA COMPANION DIAGNOSTICS MARKET, BY ONCOLOGY, 2022-2028 (IN $ MILLION)
FIGURE 13: NORTH AMERICA COMPANION DIAGNOSTICS MARKET, BY NEUROLOGY, 2022-2028 (IN $ MILLION)
FIGURE 14: NORTH AMERICA COMPANION DIAGNOSTICS MARKET, BY INFECTIOUS DISEASES, 2022-2028 (IN $ MILLION)
FIGURE 15: NORTH AMERICA COMPANION DIAGNOSTICS MARKET, BY OTHER INDICATORS, 2022-2028 (IN $ MILLION)
FIGURE 16: NORTH AMERICA COMPANION DIAGNOSTICS MARKET, OUTLOOK BY CONSUMER, 2021 & 2028 (IN %)
FIGURE 17: NORTH AMERICA COMPANION DIAGNOSTICS MARKET, BY PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES, 2022-2028 (IN $ MILLION)
FIGURE 18: NORTH AMERICA COMPANION DIAGNOSTICS MARKET, BY REFERENCE LABORATORIES, 2022-2028 (IN $ MILLION)
FIGURE 19: NORTH AMERICA COMPANION DIAGNOSTICS MARKET, BY OTHER CONSUMERS, 2022-2028 (IN $ MILLION)
FIGURE 20: NORTH AMERICA COMPANION DIAGNOSTICS MARKET, OUTLOOK BY COMMODITY, 2021 & 2028 (IN %)
FIGURE 21: NORTH AMERICA COMPANION DIAGNOSTICS MARKET, BY ASSAY KITS AND REAGENTS, 2022-2028 (IN $ MILLION)
FIGURE 22: NORTH AMERICA COMPANION DIAGNOSTICS MARKET, BY SOFTWARE AND SERVICES, 2022-2028 (IN $ MILLION)
FIGURE 23: NORTH AMERICA COMPANION DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2021 & 2028 (IN %)
FIGURE 24: UNITED STATES COMPANION DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)
FIGURE 25: CANADA COMPANION DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)

The post NORTH AMERICA COMPANION DIAGNOSTICS MARKET 2022-2028 first appeared on CRI Report.

The market for alcoholic spirits in Canada is anticipated to grow with 4.49% of CAGR (by revenue) and 1.71% of CAGR (by volume) during the forecast years between 2021 and 2026.
Due to the strong cocktail culture in Canada, there is a growing preference for high-quality products, owing to which, a number of categories saw growth in 2019. For instance, tequila (and mezcal), Irish whiskey, and single malt Scotch whisky saw healthy growth. In particular, mezcal attracted attention, with a rapidly expanding product range emerging at liquor board stores. Besides, a number of other categories, like Canadian whisky, liqueurs, vodka, and gin, observed a noticeable improvement in their growth rates.
With the implementation of the lockdown in 2020 due to Coronavirus spread, the off-trade channel witnessed growth. This growth can be attributed to consumers, especially those with higher incomes, stockpiling spirits, due to concerns regarding shortages. The off-trade channel is expected to continue to see growth, with a slightly higher rise anticipated than originally projected. Single malt Scotch whisky is expected to see strong growth, thanks to its strong off-trade performance. Also, in the forecasted period, the overall spirits category will see increased sales via grocery retailers, and the manufacturers who tap into this channel are likely to benefit.

COMPETITIVE OUTLOOK

Some of the companies operating in the alcoholic spirits market include Suntory Holdings Ltd, William Grant & Sons Ltd, Diageo Plc, Campari Milano SpA Davide, and Bacardi & Co Ltd.

TABLE OF CONTENTS

1. CANADA ALCOHOLIC SPIRITS MARKET – SUMMARY
1.1. COUNTRY SNAPSHOT
1.2. MARKET SIZE & FORECAST
1.3. MARKET DRIVING ASPECTS
1.4. MARKET RESTRAINING ASPECTS
1.5. KEY PLAYERS
2. CANADA ALCOHOLIC SPIRITS INDUSTRY OUTLOOK
2.1. IMPACT OF COVID-19 ON THE CANADA ALCOHOLIC SPIRITS INDUSTRY
2.2. PESTLE ANALYSIS
2.2.1. POLITICAL
2.2.2. ECONOMICAL
2.2.3. SOCIAL
2.2.4. TECHNOLOGICAL
2.2.5. LEGAL
2.2.6. ENVIRONMENTAL
2.3. MARKET SHARE ANALYSIS
2.4. BRAND SHARE ANALYSIS
2.5. MARKET ATTRACTIVENESS INDEX
2.6. VALUE CHAIN ANALYSIS
3. CANADA ALCOHOLIC SPIRITS MARKET – SEGMENTATION BY PRODUCT TYPE (IN TERMS OF VALUE: $ MILLION & IN TERMS OF VOLUME: MILLION LITERS)
3.1. BRANDY AND COGNAC
3.1.1. BRANDY
3.1.2. COGNAC
3.2. LIQUEURS
3.2.1. BITTERS
3.2.2. CREAM-BASED LIQUEURS
3.2.3. OTHER LIQUEURS
3.3. TEQUILA (AND MEZCAL)
3.4. RUM
3.4.1. DARK RUM
3.4.2. WHITE RUM
3.5. WHISKIES
3.5.1. BOURBON/OTHER US WHISKY
3.5.2. CANADIAN WHISKY
3.5.3. IRISH WHISKY
3.5.4. BLENDED SCOTCH WHISKY
3.5.5. SINGLE MALT SCOTCH WHISKY
3.6. WHITE SPIRITS
3.6.1. GIN
3.6.2. VODKA
3.7. OTHER SPIRITS
4. COMPETITIVE LANDSCAPE
4.1. BACARDI & CO LTD
4.2. CAMPARI MILANO SPA DAVIDE
4.3. DIAGEO PLC
4.4. WILLIAM GRANT & SONS LTD
4.5. SUNTORY HOLDINGS LTD
5. RESEARCH METHODOLOGY & SCOPE
5.1. RESEARCH SCOPE & DELIVERABLES
5.2. SOURCES OF DATA
5.3. RESEARCH METHODOLOGY

TABLE LIST

TABLE 1: CANADA ALCOHOLIC SPIRITS MARKET 2021-2026 (IN $ MILLION)
TABLE 2: CANADA – COUNTRY SNAPSHOT
TABLE 3: MARKET SHARE ANALYSIS OF KEY PLAYERS, 2018 & 2019 (IN %)
TABLE 4: BRAND SHARE ANALYSIS, 2018 & 2019 (IN %)
TABLE 5: CANADA ALCOHOLIC SPIRITS MARKET, BY PRODUCT TYPE, 2021-2026 (IN MILLION LITERS)
TABLE 6: CANADA ALCOHOLIC SPIRITS MARKET, BY PRODUCT TYPE, 2021-2026 (IN $ MILLION)
TABLE 7: CANADA ALCOHOLIC SPIRITS MARKET, BY BRANDY AND COGNAC, 2021-2026 (IN MILLION LITERS)
TABLE 8: CANADA ALCOHOLIC SPIRITS MARKET, BY BRANDY AND COGNAC, 2021-2026 (IN $ MILLION)
TABLE 9: CANADA ALCOHOLIC SPIRITS MARKET, BY LIQUEURS, 2021-2026 (IN MILLION LITERS)
TABLE 10: CANADA ALCOHOLIC SPIRITS MARKET, BY LIQUEURS, 2021-2026 (IN $ MILLION)
TABLE 11: CANADA ALCOHOLIC SPIRITS MARKET, BY RUM, 2021-2026 (IN MILLION LITERS)
TABLE 12: CANADA ALCOHOLIC SPIRITS MARKET, BY RUM, 2021-2026 (IN $ MILLION)
TABLE 13: CANADA ALCOHOLIC SPIRITS MARKET, BY WHISKIES, 2021-2026 (IN MILLION LITERS)
TABLE 14: CANADA ALCOHOLIC SPIRITS MARKET, BY WHISKIES, 2021-2026 (IN $ MILLION)
TABLE 15: CANADA ALCOHOLIC SPIRITS MARKET, BY WHITE SPIRITS, 2021-2026 (IN MILLION LITERS)
TABLE 16: CANADA ALCOHOLIC SPIRITS MARKET, BY WHITE SPIRITS, 2021-2026 (IN $ MILLION)

FIGURE LIST

FIGURE 1: CANADA ALCOHOLIC SPIRITS MARKET 2021-2026 (IN $ MILLION)
FIGURE 2: MARKET SHARE ANALYSIS OF KEY PLAYERS, 2018 & 2019 (IN %)
FIGURE 3: BRAND SHARE ANALYSIS, 2018 & 2019 (IN %)
FIGURE 4: MARKET ATTRACTIVENESS INDEX
FIGURE 5: VALUE CHAIN ANALYSIS

The post CANADA ALCOHOLIC SPIRITS MARKET 2021-2026 first appeared on CRI Report.

As per CRI’s estimates, the Mexican alcoholic ready-to-drinks (RTDs) market is anticipated to register progress at a CAGR of 3.20% in revenue and 2.29% in volume over the forecasting years between 2021 and 2026.
Despite economic slowdown owing to the COVID-19 outbreak, the alcoholic drinks industry is expected to recover significantly due to a larger, cost-effective, and less disrupted retail channel. As per estimates, off-trade sales are anticipated to witness volume sales growth. Steadier performances from alcoholic drinks are set to stabilize from 2022 as the unemployment rate lowers and disposable incomes increase. Additionally, over the forecast period, small formats of spirits are anticipated to gain traction among consumers as they are considered affordable options than well-positioned brands. Furthermore, larger and returnable formats are expected to make gains in the beer category as they offer attractive value.
As bars and restaurants slowly reopen, beer sales in on-trade are projected to grow at a steady pace. The mid-priced lagers segment will offer opportunities as the currency exchange rate is estimated to become favorable. In this regard, since the Mexican peso is appreciating against the US dollar, several brands such as Tecate, Modelo, and Victoria are expected to witness growth in terms of price-competitiveness than domestic beers. Hence, all these factors supplement the overall development of the Mexican alcoholic ready-to-drinks market.

COMPETITIVE OUTLOOK

The key firms competing in the alcoholic ready-to-drinks market include E and J Gallo Winery Inc, Brown Forman Corp, and Diageo Plc.
TABLE OF CONTENT
1. MEXICO ALCOHOLIC READY-TO-DRINKS (RTDS) MARKET – SUMMARY
1.1. COUNTRY SNAPSHOT
1.2. MARKET SIZE & FORECAST
1.3. MARKET DRIVING ASPECTS
1.4. MARKET RESTRAINING ASPECTS
1.5. KEY PLAYERS
2. MEXICO ALCOHOLIC READY-TO-DRINKS (RTDS) MARKET OUTLOOK
2.1. IMPACT OF COVID-19 ON MEXICO ALCOHOLIC RTDS MARKET
2.2. PESTLE ANALYSIS
2.2.1. POLITICAL
2.2.2. ECONOMICAL
2.2.3. SOCIAL
2.2.4. TECHNOLOGICAL
2.2.5. LEGAL
2.2.6. ENVIRONMENTAL
2.3. MARKET ATTRACTIVENESS INDEX
2.4. MARKET SHARE ANALYSIS OF KEY PLAYERS
2.5. BRAND SHARE ANALYSIS
3. MEXICO ALCOHOLIC RTDS MARKET SEGMENTATION – BY RTD TYPE (IN TERMS OF VALUE: $ MILLION & IN TERMS OF VOLUME: MILLION LITRES)
3.1. SPIRIT-BASED RTDS
3.2. WINE-BASED RTDS
4. COMPETITIVE LANDSCAPE
4.1. BROWN FORMAN CORP
4.2. PERNOD RICARD GROUPE
4.3. E AND J GALLO WINERY INC
4.4. PRODUCTOS DE UVA SA DE CV
4.5. VALLE REDONDO SA DE CV
4.6. DIAGEO PLC
5. RESEARCH METHODOLOGY & SCOPE
5.1. RESEARCH SCOPE & DELIVERABLES
5.2. SOURCES OF DATA
5.3. RESEARCH METHODOLOGY

TABLE LIST

TABLE 1: MEXICO ALCOHOLIC READY-TO-DRINKS (RTDS) MARKET 2021-2026 (IN $ MILLION)
TABLE 2: MEXICO ALCOHOLIC READY-TO-DRINKS (RTDS) MARKET 2021-2026 (IN MILLION LITRES)
TABLE 3: MEXICO – COUNTRY SNAPSHOT
TABLE 4: MARKET SHARE ANALYSIS OF KEY PLAYERS, 2018 & 2019 (IN %)
TABLE 5: BRAND SHARE ANALYSIS, 2018 & 2019 (IN %)
TABLE 6: MEXICO ALCOHOLIC READY-TO-DRINKS (RTDS) MARKET, BY RTD TYPE, 2021-2026 (IN $ MILLION)
TABLE 7: MEXICO ALCOHOLIC READY-TO-DRINKS (RTDS) MARKET, BY RTD TYPE, 2021-2026 (IN MILLION LITRES)

FIGURE LIST

FIGURE 1: MEXICO ALCOHOLIC READY-TO-DRINKS (RTDS) MARKET, 2021-2026 (IN $ MILLION)
FIGURE 2: MARKET ATTRACTIVENESS INDEX
FIGURE 3: MARKET SHARE ANALYSIS OF KEY PLAYERS, 2018 & 2019 (IN %)
FIGURE 4: BRAND SHARE ANALYSIS, 2018 & 2019 (IN %)

The post MEXICO ALCOHOLIC READY-TO-DRINKS (RTDS) MARKET 2021-2026 first appeared on CRI Report.

As per CRI’s report, the market for alcoholic ready-to-drinks (RTDs) in India is anticipated to surge at a CAGR of 10.29% in revenue over the forecast period 2021-2026. Additionally, in terms of volume, it is expected to grow at a CAGR of 12.15% during the same period.
In India, spirit-based RTDs benefit from a premium image of global brands, such as Bacardi and Smirnoff. Moreover, growing health concerns have encouraged consumers to seek lower-strength alternatives to spirits. As per estimates, the market is expected to witness new product developments over the forecast period, as several players are seeking to capitalize in the spirits segment. Magic Moments Electra is anticipated to witness strong growth among the spirits due to its high ABV and cocktail-inspired flavors.
The United Spirits is also estimated to relaunch Smirnoff Ice over the considered phase once its debt has reduced and the sales of spirit-based RTDs gain higher volume growth. Other than this, distribution is expected to widen in the on-trade and off-trade, with both channels observing robust volume growth rates. However, off-trade is set to dominate, benefitting mainly from lower costs and a wider range of brands. Thus, all these factors supplement the Indian alcoholic ready-to-drinks market’s development.

COMPETITIVE OUTLOOK

The key firms thriving in the alcoholic ready-to-drinks consist of Diageo Plc, Radico Khaitan Ltd, and Bacardi and Co Ltd.
TABLE OF CONTENT
1. INDIA ALCOHOLIC READY-TO-DRINKS (RTDS) MARKET – SUMMARY
1.1. COUNTRY SNAPSHOT
1.2. MARKET SIZE & FORECAST
1.3. MARKET DRIVING ASPECTS
1.4. MARKET RESTRAINING ASPECTS
1.5. KEY PLAYERS
2. INDIA ALCOHOLIC READY-TO-DRINKS (RTDS) MARKET OUTLOOK
2.1. IMPACT OF COVID-19 ON INDIA ALCOHOLIC RTDS MARKET
2.2. PESTLE ANALYSIS
2.2.1. POLITICAL
2.2.2. ECONOMICAL
2.2.3. SOCIAL
2.2.4. TECHNOLOGICAL
2.2.5. LEGAL
2.2.6. ENVIRONMENTAL
2.3. MARKET ATTRACTIVENESS INDEX
2.4. MARKET SHARE ANALYSIS OF KEY PLAYERS
2.5. BRAND SHARE ANALYSIS
3. INDIA ALCOHOLIC RTD MARKET SEGMENTATION – BY RTD TYPE (IN TERMS OF VALUE: $ MILLION & IN TERMS OF VOLUME: MILLION LITRES)
3.1. SPIRIT-BASED RTDS
4. COMPETITIVE LANDSCAPE
4.1. BACARDI AND CO LTD
4.2. RADICO KHAITAN LTD
4.3. DIAGEO PLC
5. RESEARCH METHODOLOGY & SCOPE
5.1. RESEARCH SCOPE & DELIVERABLES
5.2. SOURCES OF DATA
5.3. RESEARCH METHODOLOGY

TABLE LIST
TABLE 1: INDIA ALCOHOLIC READY-TO-DRINKS (RTDS) MARKET 2021-2026 (IN $ MILLION)
TABLE 2: INDIA ALCOHOLIC READY-TO-DRINKS (RTDS) MARKET 2021-2026 (IN MILLION LITRES)
TABLE 3: INDIA – COUNTRY SNAPSHOT
TABLE 4: MARKET SHARE ANALYSIS OF KEY PLAYERS, 2018 & 2019 (IN %)
TABLE 5: BRAND SHARE ANALYSIS, 2018 & 2019 (IN %)
TABLE 6: INDIA ALCOHOLIC READY-TO-DRINKS (RTDS) MARKET, BY RTD TYPE, 2021-2026 (IN $ MILLION)
TABLE 7: INDIA ALCOHOLIC READY-TO-DRINKS (RTDS) MARKET, BY RTD TYPE, 2021-2026 (IN MILLION LITRES)

FIGURE LIST
FIGURE 1: INDIA ALCOHOLIC READY-TO-DRINKS (RTDS) MARKET 2021-2026 (IN $ MILLION)
FIGURE 2: MARKET ATTRACTIVENESS INDEX
FIGURE 3: MARKET SHARE ANALYSIS OF KEY PLAYERS, 2018 & 2019 (IN %)
FIGURE 4: BRAND SHARE ANALYSIS, 2018 & 2019 (IN %)

The post INDIA ALCOHOLIC READY-TO-DRINKS (RTDS) MARKET 2021-2026 first appeared on CRI Report.

On the basis of surgery approach market is segmented into Supervisor-Controlled Surgical Systems, Shared Control Robotic Surgical Systems, Telesurgery Systems and Robotic Radiosurgery Systems. Telesurgery systems segment accounts the largest market share in 2016. A supervisor-controlled robotic surgical system is a surgical approach which offers the highest level of automation. Americas accounted for the largest market share of surgical robots market for supervisor-controlled robotic surgical system followed by Europe.

On the basis of the surgical application, the market is segmented into general surgery, cardiac surgery, gynecologic surgery, colorectal surgery, urologic surgery, head and neck surgery and other surgery. Gynaecologic surgery segment accounts the largest market share in 2016.

Key Players:
The leading market players in the global surgical robots market include Stryker, Intuitive Surgical, Inc., Mazor Robotics, Hansen Medical, TransEnterix Inc., Verb Surgical Inc. and Medtech SA.

Study objectives of surgical robots market:
• To provide insights about factors influencing and affecting the market growth
• To provide historical and forecast revenues of the market segments and sub-segments with respect to regional and country-level markets
• To provide historical and forecast revenue of the market segments based on types, products, applications, end users, and its sub-segments.
• To provide strategic profiling of key players in the market, comprehensively analyzing their market share, core competencies, and drawing a competitive landscape for the market

Target Audience:
• Medical devices manufacturers
• Medical devices distributors
• Hospitals & Clinics
• Potential investors
• Key executive (CEO and COO) and strategy growth manager

Key Findings:
• The global market for surgical robots is expected to reach USD 21,225.0 million by 2023 from USD 5,060.9 million in 2016.
• Americas commands largest market share in 2016, it is expected to reach USD 8,835.6 million by 2023.
• Asia-Pacific registers fastest growing CAGR of 23.36%% during the forecast period from 2017-2023.
The reports also cover country level analysis:
• America
• North America
• US
• Canada
• Latin America
• Europe
• Western Europe
• Germany
• France
• UK
• Italy
• Spain
• Rest Of Western Europe
• Eastern Europe
• Asia-Pacific
• Japan
• China
• India
• Republic of Korea
• Rest of Asia-Pacific
• Middle East & Africa
• UAE
• Saudi Arabia
• Egypt
• Rest of Middle East & Africa

1 REPORT PROLOGUE
1.1 INTRODUCTION
2 MARKET INTRODUCTION
2.1 INTRODUCTION
2.2 SCOPE OF STUDY
2.3 RESEARCH OBJECTIVE
2.4 ASSUMPTIONS & LIMITATIONS
2.4.1 ASSUMPTIONS
2.4.2 LIMITATIONS
2.5 MARKET STRUCTURE
3 RESEARCH METHODOLOGY
3.1 RESEARCH PROCESS
3.2 PRIMARY RESEARCH
3.3 SECONDARY RESEARCH
4 MARKET DYNAMICS
4.1 INTRODUCTION
4.2 DRIVERS
4.2.1 TECHNOLOGICAL ADVANCEMENT LED TO THE GROWTH OF THE MARKET
4.2.2 RISING DEMAND FOR MINIMALLY INVASIVE SURGERIES
4.3 RESTRAINTS
4.3.1 HIGH COST OF SURGICAL ROBOTS
4.3.2 STEEP LEARNING CURVE
4.3.3 RISKS ASSOCIATED WITH THE ROBOTIC SURGERIES
4.3.4 ATTITUDE TOWARD TECHNOLOGY
4.4 OPPORTUNITIES
4.4.1 CONSOLIDATION OF LARGE HEALTHCARE PLAYERS
4.4.2 GREATER RESEARCH AND DEVELOPMENT
4.5 CHALLENGES
4.5.1 INFANT STAGE OF DEVELOPMENT
4.5.2 CUMBERSOME SIZE AND FOOTPRINT
4.5.3 LACK OF COMPATIBLE INSTRUMENTS AND EQUIPMENT
4.6 PORTER’S FIVE FORCE ANALYSIS
4.6.1 THREAT FROM A NEW ENTRANT
4.6.2 BARGAINING POWER OF BUYER
4.6.3 BARGAINING POWER OF SUPPLIER
4.6.4 THREAT FROM SUBSTITUTE
4.6.5 INTENSITY OF COMPETITIVE RIVALRY
4.7 SUPPLY CHAIN ANALYSIS
4.7.1 RAW MATERIAL
4.7.2 SUPPLIER
4.7.3 MANUFACTURER
4.7.4 DISTRIBUTER
4.7.5 CUSTOMER
4.7.6 CONSUMER
5 GLOBAL SURGICAL ROBOTS MARKET, BY CONTROL MECHANISM
5.1 INTRODUCTION
5.2 DIRECT TELEMANIPULATOR
5.3 COMPUTER CONTROL
6 GLOBAL SURGICAL ROBOTS MARKET, BY ROBOTIC SURGERY APPROACH
6.1 INTRODUCTION
6.2 SUPERVISOR-CONTROLLED ROBOTIC SURGICAL SYSTEM
6.3 SHARED CONTROL ROBOTIC SURGICAL SYSTEMS
6.4 TELESURGERY SYSTEMS
6.5 ROBOTIC RADIOSURGERY SYSTEMS
7 GLOBAL SURGICAL ROBOTS MARKET, BY SURGICAL APPLICATION
7.1 INTRODUCTION
7.2 GENERAL SURGERY
7.3 CARDIAC SURGERY
7.4 GYNECOLOGIC SURGERY
7.5 COLORECTAL SURGERY
7.6 UROLOGIC SURGERY
7.7 HEAD AND NECK SURGERY
7.8 OTHER SURGERY
8 GLOBAL SURGICAL ROBOTS MARKET, BY REGION
8.1 INTRODUCTION
8.2 AMERICAS
8.2.1 U.S.
8.2.2 CANADA
8.2.3 LATIN AMERICA
8.3 EUROPE
8.3.1 GERMANY
8.3.2 FRANCE
8.3.3 UK
8.3.4 ITALY
8.3.5 SPAIN
8.3.6 EASTERN EUROPE
8.4 ASIA-PACIFIC
8.4.1 JAPAN
8.4.2 CHINA
8.4.3 INDIA
8.4.4 AUSTRALIA
8.4.5 REPUBLIC OF KOREA
8.4.6 REST OF ASIA-PACIFIC
8.5 MIDDLE EAST & AFRICA
8.5.1 UAE
8.5.2 SAUDI ARABIA
8.5.3 EGYPT
8.5.4 REST OF MIDDLE EAST & AFRICA
9 COMPETITIVE LANDSCAPE
9.1 INTRODUCTION
10 COMPANY PROFILE
10.1 STRYKER
10.1.1 OVERVIEW
10.1.2 PRODUCT OVERVIEW
10.1.3 FINANCIALS
10.1.4 KEY DEVELOPMENTS
10.1.5 SWOT ANALYSIS
10.2 INTUITIVE SURGICAL, INC.
10.2.1 OVERVIEW
10.2.2 PRODUCT OVERVIEW
10.2.3 FINANCIALS
10.2.4 KEY DEVELOPMENTS
10.2.5 SWOT ANALYSIS
10.3 MAZOR ROBOTICS
10.3.1 OVERVIEW
10.3.2 PRODUCT OVERVIEW
10.3.3 FINANCIALS
10.3.4 KEY DEVELOPMENTS
10.3.5 SWOT ANALYSIS
10.4 HANSEN MEDICAL
10.4.1 OVERVIEW
10.4.2 PRODUCT OVERVIEW
10.4.3 FINANCIALS
10.4.4 KEY DEVELOPMENTS
10.4.5 SWOT ANALYSIS
10.5 TRANSENTERIX, INC.
10.5.1 OVERVIEW
10.5.2 PRODUCT OVERVIEW
10.5.3 FINANCIALS
10.5.4 KEY DEVELOPMENTS
10.5.5 SWOT ANALYSIS
10.6 MEDTECH SA
10.6.1 OVERVIEW
10.6.2 PRODUCT OVERVIEW
10.6.3 FINANCIALS
10.6.4 KEY DEVELOPMENTS
10.6.5 SWOT ANALYSIS
10.7 VERB SURGICAL
10.7.1 OVERVIEW
10.7.2 PRODUCT OVERVIEW
10.7.3 FINANCIALS
10.7.4 KEY DEVELOPMENTS
10.7.5 SWOT ANALYSIS

The post Global Surgical Robots Market Research Report – Forecast to 2023 first appeared on CRI Report.

The global sports medicines market is expected to reach USD 9,655.6 million by 2023 at a CAGR of 8.9% during the forecast period.
On the basis of products, market is segmented into joint reconstructive & repair products, support & recovery products, accessories & consumables, and others. The joint reconstructive & repair products segment accounted for the largest market share of 40% during the forecast period.
On the basis of application, market is segmented into shoulder treatment, knee treatment, hip treatment, spine treatment, others. Knee treatment market is expected to grow at a CAGR of 9.3% from 2016 to 2023.
On the basis of regions, the market is segmented into Americas, Europe, Asia-Pacific and the Middle East & Africa. Americas captured a largest market share of around 39.2% in 2016 globally. The shoulder treatment market for North America was estimated at USD 562.8 Million in 2016 and is expected to reach at USD 1,055.4 Million by 2023 at a CAGR of 8.9%.
Key Players
Medtronic, Stryker, Arthrex, Inc, Zimmer Biomet, Conmed Corporation, DePuy Synthes, GE Healthcare, and Smith & Nephew plc.
Study objectives
• To provide detailed analysis of the market structure along with forecast of the various segments and sub-segments of the global sports medicines market
• To provide insights about factors influencing and affecting the market growth
• To provide historical and forecast revenue of the market segments and sub-segments with respect to countries
• To provide historical and forecast revenue of the market segments based on product, application, procedures, end user, and regions for the global sports medicines market.
• To provide strategic profiling of key players in the market, and comprehensively analysing their market share, core competencies, and drawing a competitive landscape for the market
• To provide economic factors that influences the global sports medicines market
• To provide detailed analysis of the value chain and supply chain of the global sports medicines market

Target Audience
• Sports medicines manufacturers
• Sports medicines Suppliers
• Sports medicines Distributors
• Pharmaceutical companies
• Research and Development (R&D) Companies
• Medical Research Laboratories
• Academic Medical Institutes and Universities

Key Findings
• Americas accounted for the largest market share in the global sports medicines market, USD 1,883.6 million in 2016 and expected to reach by USD 3,701.2 million by 2023 at a fastest CAGR of 8.6%
• Support & Recovery Product is the fastest growing segment with a CAGR of and 9.2% in the global sports medicines market, by product
• Ambulatory Care is growing at a CAGR of 9.3% in the global sports medicines market.

The reports also covers regional analysis
• Americas
o North America
§ US
§ Canada
o South America

• Europe
o Germany
o France
o U.K.
o Italy
o Spain
o Rest of Europe
• Asia Pacific
o Japan
o China
o India
o Republic of Korea
o Rest of Asia-Pacific
• Middle East & Africa
o Middle East
o Africa

1 Report Prologue
2 Introduction
2.1 Scope of Study
2.2 Research Objective
2.3 Assumptions & Limitations
2.3.1 Assumptions
2.3.2 Limitations
2.4 Market Structure
3 Research Methodology
3.1 Primary Research
3.2 Secondary Research
4 Market Dynamics
4.1 Drivers
4.1.1 Increasing prevalence of Sports Injuries
4.1.2 Increasing number of Sports Medicine Associations
4.1.3 Increasing Awareness
4.1.4 Technological development
4.2 Restraints
4.2.1 Lack of skilled professionals
4.2.2 High cost
4.3 Opportunities
4.3.1 Rise in influx of athletes
4.3.2 Technological advances in sports medicines
4.4 Threats
4.4.1 Introduction of small and medium sized companies
5 Market Factor Analysis
5.1 Porters Five Forces Analysis
5.1.1 Bargaining Power of Suppliers
5.1.2 Bargaining Power of Buyers
5.1.3 Threat of New Entrants
5.1.4 Threat of Substitutes
5.1.5 Intensity of Rivalry
6 Global Sports Medicine Market, By Product
6.1 Introduction
6.1.1 Joint Reconstructive & Repair Products
6.1.2 Body Support and recovery products
6.1.3 Accessories
7 Global Sports Medicines Market, By Application
7.1 Introduction
7.1.1 Shoulder Treatment
7.1.2 Knee Treatment
7.1.3 Hip Treatment
7.1.4 Spine Treatment
8 Global Sports Medicines Market, by Procedures
8.1 Introduction
8.1.1 Tendinosis
8.1.2 Tendon to Bone
8.1.3 Cartilage repair
9 Global Sports Medicines Market, By End User
9.1 Introduction
9.1.1 Hospital & Emergency Care
9.1.2 Trauma center
9.1.3 Ambulatory Care
10 Global Sports Medicine Market, By Region
10.1 Introduction
10.2 North America
10.2.1 Introduction
10.2.2 U.S.
10.2.3 Canada
10.2.4 South America
10.3 Europe
10.3.1 Introduction
10.3.2 Germany
10.3.3 France
10.3.4 U.K.
10.3.5 Italy
10.3.6 Spain
10.3.7 Rest of Western Europe
10.3.8 Eastern Europe
10.4 Asia-Pacific
10.4.1 Introduction
10.4.2 Japan
10.4.3 China
10.4.4 India
10.4.5 Republic of Korea
10.4.6 Australia
10.4.7 Rest of Asia Pacific
10.5 Middle East & Africa
10.5.1 Introduction
10.5.2 Middle East
10.5.3 Africa
11 Company Landscape
11.1 Introduction
12 Company Profile
12.1 Medtronics
12.1.1 Company Overview
12.1.2 Product/Business Segment Overview
12.1.3 Financial Overview
12.1.4 Key Development
12.2 Stryker
12.2.1 Company Overview
12.2.2 Product/Business Segment Overview
12.2.3 Financial Overview
12.2.4 Key Development
12.3 Zimmer Biomet
12.3.1 Company Overview
12.3.2 Product/Business Segment Overview
12.3.3 Financial Overview
12.3.4 Key Development
12.4 Conmed Corporation
12.4.1 Company Overview
12.4.2 Product/Business Segment Overview
12.4.3 Financial Overview
12.4.4 Key Development
12.5 DePuy Synthes
12.5.1 Company Overview
12.5.2 Product/Business Segment Overview
12.5.3 Financial Overview
12.5.4 Key Development
12.6 GE Healthcare
12.6.1 Company Overview
12.6.2 Product/Business Segment Overview
12.6.3 Financial Overview
12.6.4 Key Development
12.7 Smith & Nephew plc
12.7.1 Company Overview
12.7.2 Product Overview
12.7.3 Financials
12.7.4 Key Developments
12.8 Arthrex, Inc.
12.8.1 Company Overview
12.8.2 Product/Business Segment Overview
12.8.3 Financial Overview
12.8.4 Key Development

The post Global Sports Medicine Market Research Report – Forecast to 2023 first appeared on CRI Report.